All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Flavonol glycoside analouges
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: ActoPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 26, 2021
Details:
The biopharmaceutical formulation consisting of two flavanol glycoside analogues is designed to simultaneously reduce viral load, decrease platelet aggregation and modulate the cytokine ratios in order to effectively suppress cytokine storm.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ibudilast,Interferon-beta
Therapeutic Area: Immunology Product Name: MN-166
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 29, 2020
Details:
The allowed claims cover a method of alleviating the negative effects of progressive multiple sclerosis, treating progressive multiple sclerosis, or slowing the progression of progressive multiple sclerosis by administering MN-166 and interferon-beta in separate dosage forms.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TRK-001
Therapeutic Area: Immunology Product Name: TRK-001
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
TRK-001 is an autologous regulatory T-cell therapy that utilizes a patient’s own cells that are expanded ex vivo and infused back into the patient after a solid organ transplant.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
Details:
The preclinical results described in the publications were used to support the advancement of BRYN-NDS1C into the human clinical trial program currently underway.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ADP101
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Gurnet Point Capital
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing February 20, 2020
Details:
Proceeds to support clinical advancement of ADP101, a broad-spectrum oral biopharmaceutical candidate targeting food allergy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Treg therapy
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Lyell Immunopharma
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 06, 2020
Details:
The series A funding is to advance regulatory T cell therapy in autoimmune and degenerative diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): T cells therapy
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vida Ventures
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 13, 2020
Details:
Proceeds from the financing will be used to advance Kyverna's therapeutic strategy which combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate autoreactive immune cells at the root cause of inflammatory disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): T cells therapy
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $587.5 million Upfront Cash: $17.5 million
Deal Type: Collaboration January 13, 2020
Details:
Kyverna will be conducting research activities and initial clinical studies through proof-of-concept and Gilead will be granted an option for further development and commercialization of these programs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: SAB Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 07, 2020
Details:
The collaborations will explore the possibility and the potential of new therapies to treat challenging autoimmune, infectious and idiopathic diseases by leveraging SAB’s DiversitAb™ platform.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
